InvestorsHub Logo

THEBEASTMUGABI

09/27/18 4:22 PM

#1704 RE: H2R #1703

Now let’s see if they sit on it for a year and do nothing. Again !

H2R

09/27/18 4:30 PM

#1705 RE: H2R #1703

Up Next: Sandoz to announce commercial plan and launch!
That should be the next catalyst IHMO.

The FDA approves Adamis Pharmaceuticals' (NASDAQ:ADMP) lower-dose version (0.15 mg) of emergency allergic reaction med Symjepi (epinephrine) for pediatric use.

Novartis (NYSE:NVS) unit Sandoz will commercialize.

ADMP will resume trading at 4:25 pm ET.



Best of luck to Longs!

XenaLives

12/31/18 11:26 AM

#1731 RE: H2R #1703

Viable competition to the EpiPen is a social good..

I like stocks that do the right thing and make money too.